KRAS and non-small cell lung carcinoma: Sotorasib (ClinicalTrials.gov NCT03600883) and MRTX849 (NCT03785249) are being evaluated in phase I/II clinical trials in patients with advanced KRAS G12C–mutant solid tumors, particularly those with NSCLC.